X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs UNICHEM LAB - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA UNICHEM LAB ASTRAZENECA PHARMA/
UNICHEM LAB
 
P/E (TTM) x 92.1 241.8 38.1% View Chart
P/BV x 20.3 0.6 3,123.1% View Chart
Dividend Yield % 0.0 2.1 -  

Financials

 ASTRAZENECA PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
UNICHEM LAB
Mar-19
ASTRAZENECA PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,278292 437.7%   
Low Rs883182 484.9%   
Sales per share (Unadj.) Rs228.4167.7 136.2%  
Earnings per share (Unadj.) Rs10.4-3.6 -285.5%  
Cash flow per share (Unadj.) Rs16.35.9 273.7%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs98.8372.3 26.5%  
Shares outstanding (eoy) m25.0070.38 35.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.71.4 334.6%   
Avg P/E ratio x104.2-65.3 -159.7%  
P/CF ratio (eoy) x66.439.9 166.6%  
Price / Book Value ratio x10.90.6 1,717.9%  
Dividend payout %0-110.2 0.0%   
Avg Mkt Cap Rs m27,00816,680 161.9%   
No. of employees `0001.42.6 52.1%   
Total wages/salary Rs m1,5352,393 64.2%   
Avg. sales/employee Rs Th4,210.94,535.2 92.9%   
Avg. wages/employee Rs Th1,132.2919.8 123.1%   
Avg. net profit/employee Rs Th191.1-98.2 -194.6%   
INCOME DATA
Net Sales Rs m5,71011,801 48.4%  
Other income Rs m123984 12.4%   
Total revenues Rs m5,83312,785 45.6%   
Gross profit Rs m463-835 -55.4%  
Depreciation Rs m147674 21.9%   
Interest Rs m075 0.0%   
Profit before tax Rs m438-600 -73.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-343 -52.1%   
Profit after tax Rs m259-256 -101.4%  
Gross profit margin %8.1-7.1 -114.6%  
Effective tax rate %40.857.3 71.3%   
Net profit margin %4.5-2.2 -209.6%  
BALANCE SHEET DATA
Current assets Rs m3,20920,384 15.7%   
Current liabilities Rs m2,0705,029 41.1%   
Net working cap to sales %20.0130.1 15.3%  
Current ratio x1.64.1 38.3%  
Inventory Days Days72105 69.0%  
Debtors Days Days35135 25.9%  
Net fixed assets Rs m7909,023 8.8%   
Share capital Rs m50141 35.5%   
"Free" reserves Rs m2,41926,058 9.3%   
Net worth Rs m2,46926,199 9.4%   
Long term debt Rs m00-   
Total assets Rs m4,60531,496 14.6%  
Interest coverage xNM-7.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.4 330.9%   
Return on assets %5.6-0.6 -982.6%  
Return on equity %10.5-1.0 -1,075.8%  
Return on capital %17.7-2.0 -887.2%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3008,188 3.7%   
Fx outflow Rs m2,015596 338.1%   
Net fx Rs m-1,7157,592 -22.6%   
CASH FLOW
From Operations Rs m88-3,278 -2.7%  
From Investments Rs m-94-2,860 3.3%  
From Financial Activity Rs mNA-24 0.0%  
Net Cashflow Rs m-6-4,690 0.1%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 15.1 2.0%  
FIIs % 15.7 3.0 523.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 31.7 28.7%  
Shareholders   12,856 20,176 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 17, 2019 03:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS